Wellbutrin Linked To Serious Heart Problems For Newborns
Wellbutrin (Bupropion HCI), which is manufactured by GlaxoSmithKline, was first approved by the FDA as an antidepressant in December 1985. A new study published in the American Journal of Obstetrics & Gynecology has suggested that women who use the antidepressant early on in the pregnancy have an increased risk of having a baby with a heart defect. Researchers found that more than 12,700 infants born from 1997 to 2004 in the United States whose mothers were taking Wellbutrin during the pregnancy, had more than double the risk of a heart defect known as left outflow defects.
Outflow Defect affects the blood-flow from the hearts left chambers to the rest of the body. The most common type of heart defect cited within this study was coarctation of the aorta, which is a congenital heart defect involving a narrowing of the aorta usually requiring surgery. According to experts, the risk of this heart defect is small, effecting just 2 out of every 1,000 infants born to women who used Wellbutrin during the first trimester.
Studies have already linked other antidepressants including selective serotonin reuptake inhibitors (SSRIs) to the risks of heart and lung birth defects such as:
Those who took Wellbutrin (bupropion) during their pregnancy and their baby was born with a birth defect, may contact Wellbutrin Information, for a no-obligation legal consultation. They and their families have legal rights. To learn more, email Wellbutrin Information directly at: WellbutrinInformation@Gmail.com
- Contact Information
- Josh Rider
- Wellbutrin Information
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.